Apomorphine sublingual film - Sunovion Pharmaceuticals

Drug Profile

Apomorphine sublingual film - Sunovion Pharmaceuticals

Alternative Names: APL-130277; Apomorphine Hydrochloride Sublingual Thin Film

Latest Information Update: 31 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adagio Pharmaceuticals
  • Developer Sunovion Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 29 Jan 2018 Apomorphine sublingual film - Sunovion Pharmaceuticals receives Fast Track designation for Parkinson's disease [Sublingual,Film] in USA
  • 29 Jan 2018 Sunovion Pharmaceuticals announces intention to file NDA with the US FDA for Parkinson's disease by May 2018
  • 29 Jan 2018 Top-line safety, and efficacy data from the phase III CTH-300 trial in Parkinson's disease released by Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top